Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications

Experimental Cell Research

Volumn 318, Issue 19, 2012, Pages 2417-2426

  Yang, Liuqi ^a   Lin, Caiyu ^a   Wang, Li ^a   Guo, Huijie ^a   Wang, Xiujie ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Glioblastoma multiforme; Glioma stem cells; Hypoxia; Hypoxia inducible factors; Targeting therapy

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CARBONATE DEHYDRATASE IX; CD133 ANTIGEN; GELATINASE B; HISTONE H2AX; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR 3ALPHA; MESSENGER RNA; MIXED LINEAGE LEUKEMIA PROTEIN; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAD51 PROTEIN; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; TRANSCRIPTION FACTOR NFAT; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; BRAIN HYPOXIA; CANCER INVASION; CANCER PROGNOSIS; CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; DIMERIZATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HYDROXYLATION; METABOLISM; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; RNA INTERFERENCE; STEM CELL NICHE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; UPREGULATION;

EID: 84866340817     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.07.017     Document Type: Review

References (100)

1. Koritzinsky M., Seigneuric R., Magagnin M.G., van den Beucken T., Lambin P., Wouters B.G. The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiother. Oncol. 2005, 76:177-186.
2. Jögi A., Øra I., Nilsson H., Lindeheim A., Makino Y., Poellinger L., Axelson H., Påhlman S. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:7021-7026.
3. Gopal U., Bohonowych J.E., Lema-Tome C., Liu A., Garrett-Mayer E., Wang B., Isaacs J.S. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLoS One 2011, 6:e17649.
4. Kawai N., Maeda Y., Kudomi N., Miyake K., Okada M., Yamamoto Y., Nishiyama Y., Tamiya T. Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:441-450.
5. Bao B., Azmi A.S., Ali S., Ahmad A., Li Y., Banerjee S., Kong D., Sarkar F.H. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim. Biophys. Acta 2012, 1826:272-296.
6. Daumas-Duport C., Scheithauer B., O'Fallon J., Kelly P. Grading of astrocytomas, a simple and reproducible method. Cancer 1988, 62:2152-2165.
7. Rong Y., Durden D.L., Van Meir E.G., Brat D.J. Pseudopalisading necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J. Neuropathol. 2006, 6:529-539.
8. Merighi S., Benini A., Mirandola P., Gessi S., Varani K., Leung E., Maclennan S., Borea Adenosine P.A. modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem. Pharmacol. 2006, 72:19-31.
9. López-Lázaro M. Hypoxia-inducible factor 1 as a possible target for cancer chemoprevention. Cancer Epidemiol. Biomarkers Prev. 2006, 15:2232-2235.
10. Hsieh C.H., Shyu W.C., Chiang C.Y., Kuo J.W., Shen W.C., Liu R.S. NADPH oxidase subunit 4-mediated reactive oxygen species contribute to cycling hypoxia-promoted tumor progression in glioblastoma multiforme. PLoS One 2011, 6:e23945.
11. Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., Stegh A., Hahn W.C., Ligon K.L., Louis D.N., Brennan C., Chin L., DePinho R.A., Cavenee W.K. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007, 21:2683-2710.
12. Galli R., Binda E., Orfanelli U., Cipelletti B., Gritti A., De Vitis S., Fiocco R., Foroni C., Dimeco F., Vescovi A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004, 64:7011-7021.
13. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
14. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
15. Cheng L., Wu Q., Guryanova O.A., Huang Z., Huang Q., Rich J.N., Bao S. Elevated invasive potential of glioblastoma stem cells. Biochem. Biophys. Res. Commun. 2011, 406:643-648.
16. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 21:38-47.
17. Vaupe P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004, 9:10-17.
18. Keith B., Simon M.C. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129:465-472.
19. Ao J.E., Kuang L.H., Zhou Y., Zhao R., Yang C.M. Hypoxia-inducible factor 1 regulated ARC expression mediated hypoxia induced inactivation of the intrinsic death pathway in p53 deficient human colon cancer cells. Biochem. Biophys. Res. Commun. 2012, 420:913-917.
20. Xue X., Taylor M., Anderson E., Hao C., Qu A., Greenson J.K., Zimmermann E.M., Gonzalez F.J., Shah Y.M. HIF-2α activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res. 2012, 72:2285-2293.
21. Liu Y., Bernauer A.M., Yingling C.M., Belinsky S.A. HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer. Carcinogenesis 2012, 33:1187-1192.
22. Zagzag D., Lukyanov Y., Lan L., Ali M.A., Esencay M., Mendez O., Yee H., Voura E.B., Newcomb E.W. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab. Invest. 2006, 86:1221-1232.
23. Jiang B.H., Rue E., Wang G.L., Roe R., Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 1996, 271:17771-17778.
24. Michel G., Minet E., Ernest I., Roland I., Durant F., Remacle J., Michiels C. A model for the complex between the hypoxia-inducible factor-1 (HIF-1) and its consensus DNA sequence. J. Biomol. Struct. Dyn. 2000, 18:169-179.
25. Mabjeesh N.J., Amir S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol. Histopathol. 2007, 22:559-572.
26. Li Z., Bao S., Wu Q., Wang H., Eyler C., Sathornsumetee S., Shi Q., Cao Y., Lathia J., McLendon R.E., Hjelmeland A.B., Rich J.N. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15:501-513.
27. Kaur B., Khwaja F.W., Severson E.A., Matheny S.L., Brat D.J., Van Meir E.G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol. 2007, 7:134-153.
28. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
29. Lu H., Li Y., Shu M., Tang J., Huang Y., Zhou Y., Liang Y., Yan G. Hypoxia-inducible factor-1alpha blocks differentiation of malignant gliomas. FEBS J. 2009, 276:7291-7304.
30. Méndez O., Zavadil J., Esencay M., Lukyanov Y., Santovasi D., Wang S.C., Newcomb E.W., Zagzag D. Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol. Cancer 2010, 9:133.
31. Bar E.E., Lin A., Mahairaki V., Matsui W., Eberhart C.G. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am. J. Pathol. 2010, 177:1491-1502.
32. Heddleston J.M., Wu Q., Rivera M., Minhas S., Lathia J.D., Sloan A.E., Iliopoulos O., Hjelmeland A.B., Rich J.N. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ. 2012, 19:428-439.
33. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:7987-7992.
34. Kallio P.J., Wilson W.J., O'Brien S., Makino Y., Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J. Biol. Chem. 1999, 274:6519-6525.
35. Mahon P.C., Hirota K., Semenza G.L. FIH-1: a novel protein that interacts with HIF-1 and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001, 15:2675-2686.
36. Lando D., Peet D.J., Whelan D.A., Gorman J.J., Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 2002, 295:858-861.
37. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 2002, 8:S62-S67.
38. Oliver L., Olivier C., Marhuenda F.B., Campone M., Vallette F.M. Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Curr. Mol. Pharmacol. 2009, 2:263-284.
39. Brat D.J., Mapstone T.B. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann. Intern. Med. 2003, 138:659-668.
40. Flamme I., Krieg M., Plate K.H. Up-regulation of vascular endothelial growth factor in stromal cells of human gioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2α. Am. J. Pathol. 1998, 153:25-29.
41. Jensen R.L., Ragel B.T., Whang K., Gillespie D. Inhibition of hypoxia-inducible factor-1a (HIF-1α) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J. Neurooncol. 2006, 78:233-247.
42. Argyriou A.A., Giannopoulou E., Kalofonos H.P. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas. Oncology 2009, 77:1-11.
43. Dvorak H.F. Angiogenesis: update. J. Thromb. Haemost. 2005, 3(2005):1835-1842.
44. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 1996, 16:4604-4613.
45. Gleadle J.M., Ratcliffe P.J. Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. Blood 1997, 89:503-509.
46. Cassavaugh J., Lounsbury K.M. Hypoxia-mediated biological control. J. Cell Biochem. 2011, 112:735-744.
47. Semenza G.L. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 2008, 60:591-597.
48. Jensen R.L. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J. Neurooncol. 2009, 92:317-335.
49. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W., Semenza G.L. Expression of hypoxia-inducible factor 1 alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000, 88:2606-2618.
50. Pietsch T., Valter M.M., Wolf H.K., von Deimling A., Huang H.J., Cavenee W.K., Wiestler O.D. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol. 1997, 93:109-117.
51. Chaudhry I.H., O'Donovan D.G., Brenchley P.E., Reid H., Roberts I.S. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001, 39:409-415.
52. Hueng D.Y., Lin G.J., Huang S.H., Liu L.W., Ju D.T., Chen Y.W., Sytwu H.K., Chang C., Huang S.M., Yeh Y.S., Lee H.M., Ma H.I. Inhibition of Nodal suppresses angiogenesis and growth of human gliomas. J. Neurooncol. 2011, 104:21-31.
53. Fischer I., Gagner J.P., Law M., Newcomb E.W., Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol. 2005, 15:297-310.
54. Plate K.H., Breier G., Weich H.A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845-848.
55. Dreyfuss J.M., Johnson M.D., Park P.J. Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol. Cancer 2009, 8:71.
56. Fiorenzo P., Mongiardi M.P., Dimitri D., Cozzolino M., Ferri A., Montano N., Trevisi G., Maira G., Battistini L., Falchetti M.L., Levi A., Pallini R. HIF1-positive and HIF1-negative glioblastoma cells compete in vitro but cooperate in tumor growth in vivo. Int. J. Oncol. 2010, 36:785-791.
57. Acker T., Diez-Juan A., Aragones J., Tjwa M., Brusselmans K., Moons L., Fukumura D., Moreno-Murciano M.P., Herbert J.M., Burger A., Riedel J., Elvert G., Flamme I., Maxwell P.H., Collen D., Dewerchin M., Jain R.K., Plate K.H., Carmeliet P. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 2005, 8:131-141.
58. Said H.M., Supuran C.T., Hageman C., Staab A., Polat B., Katzer A., Scozzafava A., Anacker J., Flentje M., Vordermark D. Modulation of carbonic anhydrase 9 (CA9) in human brain cancer. Curr. Pharm. Des. 2010, 16:3288-3299.
59. Chigurupati S., Venkataraman R., Barrera D., Naganathan A., Madan M., Paul L., Pattisapu J.V., Kyriazis G.A., Sugaya K., Bushnev S., Lathia J.D., Rich J.N., Chan S.L. Receptor channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and invasiveness. Cancer Res. 2010, 70:418-427.
60. Ponnala S., Veeravalli K.K., Chetty C., Dinh D.H., Rao J.S. Regulation of DNA repair mechanism in human glioma xenograft cells both in vitro and in vivo in nude mice. PLoS One 2011, 6:e26191.
61. Lathia J.D., Heddleston J.M., Venere M., Rich J.N. Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell 2011, 8:482-485.
62. Seidel S., Garvalov B.K., Wirta V., von Stechow L., Schänzer A., Meletis K., Wolter M., Sommerlad D., Henze A.T., Nistér M., Reifenberger G., Lundeberg J., Frisén J., Acker T. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010, 133(Pt 4):983-995.
63. Anido J., Sáez-Borderías A., Gonzàlez-Juncà A., Rodón L., Folch G., Carmona M.A., Prieto-Sánchez R.M., Barba I., Martínez-Sáez E., Prudkin L., Cuartas I., Raventós C., Martínez-Ricarte F., Poca M.A., García-Dorado D., Lahn M.M., Yingling J.M., Rodón J., Sahuquillo J., Baselga J., Seoane J. TGF-Β receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 2010, 18:655-668.
64. Yu S.P., Yang X.J., Zhang B., Ming H.L., Chen C., Ren B.C., Liu Z.F., Liu B. Enhanced invasion in vitro and the distribution patterns in vivo of CD133+ glioma stem cells. Chin. Med. J. (Engl.) 2011, 124:2599-2604.
65. Bao S., Wu Q., Sathornsumetee S., Hao Y., Li Z., Hjelmeland A.B., Shi Q., McLendon R.E., Bigner D.D., Rich J.N. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006, 66:7843-7848.
66. Platet N., Liu S.Y., Atifi M.E., Oliver L., Vallette F.M., Berger F., Wion D. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett. 2007, 258:286-290.
67. Gilbertson R.J., Rich J.N. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 2007, 7:733-736.
68. McCord A.M., Jamal M., Shankavaram U.T., Lang F.F., Camphausen K., Tofilon P.J. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol. Cancer Res. 2009, 7:489-497.
69. Soeda A., Park M., Lee D., Mintz A., Androutsellis-Theotokis A., McKay R.D., Engh J., Iwama T., Kunisada T., Kassam A.B., Pollack I.F., Par D.M. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1αlpha. Oncogene 2009, 28:3949-3959.
70. Birner P., Piribauer M., Fischer I., Gatterbauer B., Marosi C., Ambros P.F., Ambros I.M., Bredel M., Oberhuber G., Rössler K., Budka H., Harris A.L., Hainfellner J.A. Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol. 2003, 13:133-143.
71. Sathornsumetee S., Cao Y., Marcello J.E., Herndon J.E., McLendon R.E., Desjardins A., Friedman H.S., Dewhirst M.W., Vredenburgh J.J., Rich J.N. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol. 2008, 26:271-278.
72. Ducray F., de Reyniès A., Chinot O., Idbaih A., Figarella-Branger D., Colin C., Karayan-Tapon L., Chneiweiss H., Wager M., Vallette F., Marie Y., Rickman D., Thomas E., Delattre J.Y., Honnorat J., Sanson M., Berger F. An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Mol. Cancer 2010, 9:234.
73. Heddleston J.M., Li Z., McLendon R.E., Hjelmeland A.B., Rich J.N. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009, 8:3274-3284.
74. Qiang L., Wu T., Zhang H.W., Lu N., Hu R., Wang Y.J., Zhao L., Chen F.H., Wang X.T., You Q.D., Guo Q.L. HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ. 2012, 19:284-294.
75. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegué E., Song H., Vandenberg S., Johnson R.S., Werb Z., Bergers G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
76. Gillespie D.L., Whang K., Ragel B.T., Flynn J.R., Kelly D.A., Jensen R.L. Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin. Cancer Res. 2007, 13:2441-2448.
77. Irie N., Matsuo T., Nagata I. Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathol. 2004, 21:1-6.
78. Stoeltzing O., McCarty M.F., Wey J.S., Fan F., Liu W., Belcheva A., Bucana C.D., Semenza G.L., Ellis L.M. Role of hypoxia-inducible factor 1a in gastric cancer cell growth, angiogenesis, and vessel maturation. J. Natl. Cancer Inst. 2004, 96:946-956.
79. Li L., Lin X., Staver M., Shoemaker A., Semizarov D., Fesik S.W., Shen Y. Evaluating hypoxia-inducible factor 1a as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res. 2005, 65:7249-7258.
80. Hiraga T., Kizaka-Kondoh S., Hirota K., Hiraoka M., Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 2007, 67:4157-4163.
81. Liao D., Corle C., Seagroves T.N., Johnson R.S. Hypoxia-inducible factor 1a is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 2007, 67:563-572.
82. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., Gottschalk A.R., Ryan H.E., Johnson R.S., Jefferson A.B., Stokoe D., Giaccia A.J. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000, 14:391-396.
83. Kang S.H., Cho H.T., Devi S., Zhang Z., Escuin D., Liang Z., Mao H., Brat D.J., Olson J.J., Simons J.W., Lavallee T.M., Giannakakou P., Van Meir E.G., Shim H. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res. 2006, 66:11991-11997.
84. Jensen R.L. Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg. Focus 2006, 20:E24.
85. Kaluz S., Kaluzová M., Stanbridge E.J. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1α C-terminal activation domain. Mol. Cell Biol. 2006, 26:5895-5907.
86. Yeo E.J., Ryu J.H., Cho Y.S., Chun Y.S., Huang L.E., Kim M.S., Park J.W. Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 2006, 107:916-923.
87. Kirkpatrick J., Desjardins A., Quinn J., Rich J., Vredenburgh J., Sathornsumetee S., Gururangan S., Sidor C., Friedman H., Reardon D. Phase II open-label, safety, pharmacokinetic and efficacy study of 2-methoxyestradiol nanocrystal colloidal dispersion administered orally to patients with recurrent glioblastoma multiforme. J. Clin. Oncol. 2007, 25:2065. (Meeting Abstracts).
88. Kong D., Park E.J., Stephen A.G., Calvani M., Cardellina J.H., Monks A., Fisher R.J., Shoemaker R.H., Melillo G. Echinomycin, a small-molecule inhibitor of hypoxia inducible factor-1 DNA-binding activity. Cancer Res. 2005, 65:9047-9055.
89. Blum R., Jacob-Hirsch J., Amariglio N., Rechavi G., Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res. 2005, 65:999-1006.
90. Kioi M., Vogel H., Schultz G., Hoffman R.M., Harsh G.R., Brown J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 2010, 120:694-705.
91. Pistollato F., Rampazzo E., Abbadi S., Della Puppa A., Scienza R., D'Avella D., Denaro L., Te Kronnie G., Panchision D.M., Basso G. Molecular mechanisms of HIF-1alpha modulation induced by oxygen tension and BMP2 in glioblastoma derived cells. PLoS One 2009, 4:e6206.
92. Bleau A.M., Hambardzumyan D., Ozawa T., Fomchenko E.I., Huse J.T., Brennan C.W., Holland E.C. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4:226-235.
93. Bao S., Wu Q., Li Z., Sathornsumetee S., Wang H., McLendon R.E., Hjelmeland A.B., Rich J.N. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008, 68:6043-6048.
94. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., Lu L., Irvin D., Black K.L., Yu J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5:67.
95. Hofstetter C.P., Burkhardt J.K., Shin B.J., Gürsel D.B., Mubita L., Gorrepati R., Brennan C., Holland E.C., Boockvar J.A. Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia. PLoS One 2012, 7:e30059.
96. Ricci-Vitiani L., Pallini R., Biffoni M., Todaro M., Invernici G., Cenci T., Maira G., Parati E.A., Stassi G., Larocca L.M., De Maria R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828.
97. Folkins C., Shaked Y., Man S., Tang T., Lee C.R., Zhu Z., Hoffman R.M., Kerbel R.S. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res. 2009, 69:7243-7251.
98. Holmquist-Mengelbier L., Fredlund E., Löfstedt T., Noguera R., Navarro S., Nilsson H., Pietras A., Vallon-Christersson J., Borg A., Gradin K., Poellinger L., Påhlman S. Recruitment of HIF-1αlpha and HIF-2αlpha to common target genes is differentially regulated in neuroblastoma: HIF-2αlpha promotes an aggressive phenotype. Cancer Cell 2006, 10:413-423.
99. Gordan J.D., Bertout J.A., Hu C.J., Diehl J.A., Simon M.C. HIF-2αlpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007, 11:335-347.
100. Mao X.G., Yan M., Xue X.Y., Zhang X., Ren H.G., Guo G., Wang P., Zhang W., Huo J.L. Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. Lab. Invest. 2011, 91:1068-1078.